<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118531</url>
  </required_header>
  <id_info>
    <org_study_id>MDT16003RES001</org_study_id>
    <nct_id>NCT03118531</nct_id>
  </id_info>
  <brief_title>China Resolute Integrity 34/38 mm Study</brief_title>
  <official_title>Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical safety and efficacy in Chinese subjects, eligible for percutaneous
      transluminal coronary angioplasty (PTCA) in lesions amenable to treatment with a 34/38 mm
      Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late lumen loss, in stent</measure>
    <time_frame>9 months (m)</time_frame>
    <description>Late lumen loss measured by quantitative coronary angiography (QCA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days, 6 and 9 months, 1, 2, 3, 4, and 5 years</time_frame>
    <description>Defined as death, myocardial infarction (Q wave and non-Q wave), or clinically-driven repeat target lesion revascularization by percutaneous or surgical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>30 days, 6 and 9 months, 1, 2, 3, 4, and 5 years</time_frame>
    <description>All death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30 days, 6 and 9 months, 1, 2, 3, 4, and 5 years</time_frame>
    <description>All MI, and Target Vessel Myocardial Infarction (TVMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All revascularizations</measure>
    <time_frame>30 days, 6 and 9 months, 1, 2, 3, 4, and 5 years</time_frame>
    <description>Target Legion Revascularization (TLR), Target Vessel Revascularization (TVR) and Non-TVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>30 days, 6 and 9 months, 1, 2, 3, 4, and 5 years</time_frame>
    <description>TVF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>30 days, 6 and 9 months, 1, 2, 3, 4, and 5 years</time_frame>
    <description>TLF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis (ST)</measure>
    <time_frame>30 days, 6 and 9 months, 1, 2, 3, 4, and 5 years</time_frame>
    <description>ST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>At the end of index procedure, an expected average of 3 days</time_frame>
    <description>The attainment of &lt;50% residual stenosis of the target lesion using only the assigned device.
The attainment of &lt; 30% residual stenosis by QCA (or &lt; 20% by visual assessment) AND a TIMI flow 3 after the procedure, using the assigned device only. These measurements will be made by the independent angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion Success</measure>
    <time_frame>At the end of index procedure, an expected average of 3 days</time_frame>
    <description>The attainment of &lt;50% residual stenosis of the target lesion using any percutaneous method.
The attainment of &lt; 30% residual stenosis by QCA (or &lt; 20% by visual assessment) AND a TIMI flow 3 after the procedure, using any percutaneous method. These measurements will be made by the independent angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>Duration of hospital stay, an expected average of 5 days</time_frame>
    <description>The attainment of &lt;50% residual stenosis of the target lesion and no in-hospital MACE.
The attainment of &lt; 30% residual stenosis by QCA (or &lt; 20% by visual assessment) AND a TIMI flow 3 after the procedure, using any percutaneous method without the occurrence of MACE during the hospital stay. These measurements will be made by the independent angiographic core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment percent diameter stenosis (%DS)</measure>
    <time_frame>9 months</time_frame>
    <description>In-stent and in-segment percent diameter stenosis (%DS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment binary restenosis rate</measure>
    <time_frame>9 months</time_frame>
    <description>In-stent and in-segment binary restenosis rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent and in-segment minimal luminal diameter (MLD)</measure>
    <time_frame>9 months</time_frame>
    <description>In-stent and in-segment minimal luminal diameter (MLD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment late luminal loss</measure>
    <time_frame>9 months</time_frame>
    <description>In-segment late luminal loss</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Stenotic Coronary Lesion</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Coronary Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System (34/38 mm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)</intervention_name>
    <description>The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.</description>
    <arm_group_label>Coronary Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  The subject is an acceptable candidate for treatment with a drug-eluting stent in
             accordance with the applicable guidelines on percutaneous coronary interventions, the
             Instructions for Use of the Resolute Integrity 34/38 mm stent

          -  The subject can have either a single lesion, or two lesions located in separate target
             vessels treated during the index procedure. Each lesion length needs to be ≤35mm with
             at least one lesion length &gt;27mm and≤ 35mm and amenable for treatment with a Resolute
             Integrity 34/38 mm stent

        Key Exclusion Criteria:

          -  STEMI within 24 hours

          -  Left main disease

          -  Bifurcation disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lianglong Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Asia Heart Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long Lesion</keyword>
  <keyword>In-stent Late Lumen Loss (LLL)</keyword>
  <keyword>Major Adverse Cardiac Events (MACE)</keyword>
  <keyword>MYOCARDIAL INFARCTION (MI)</keyword>
  <keyword>TARGET VESSEL REVASCULARIZATION (TVR)</keyword>
  <keyword>TARGET LESION REVASCULARIZATION (TLR)</keyword>
  <keyword>Target Vessel Failure (TVF)</keyword>
  <keyword>Target Lesion Failure (TLF)</keyword>
  <keyword>Stent Thrombosis (ST)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

